OnEMI Technology Solutions Limited moves to reshape its capital structure

Allottees: The proposed issue is entirely to external, non-promoter investors—not to promoters. It covers up to 26,493,882 equity shares to 34 non-promoter investors, subject to shareholder and regulatory approvals ^[1]. Reported participants include Axis Mutual Fund, HDFC Mutual Fund, Groww Mutual Fund, 360 One Equity Opportunity Fund, WhiteOak funds, Citigroup Global Markets Hong Kong, MIT, Nippon India Equity Opportunities AIF, Unity Small Finance Bank and Envision India Fund ^[1].

Dilution calculation:

• Current equity share capital: Rs 16.85 Crores ^[2]
• Face value: Rs 1 per share ^[3]
• Implied existing shares: 168.50 million
• New shares: 26.493882 million ^[3]
• Post-issue shares: 194.993882 million

Result: Existing shareholders would own approximately 86.41% post issue, implying 13.59% dilution on a post-issue share-count basis:

`26.493882 / (168.50 + 26.493882) = 13.59%`

For clarity, the new issue represents 15.72% of the pre-issue share capital; the economically relevant dilution to existing holders is 13.59% because the denominator expands after the issue.

The filing evidence available does not quantify any portion of the proceeds allocated to augmenting Tier-I capital, nor does it disclose the company’s pre- or post-issue CAR.

For the proposed preferential issue, OnEMI planned to raise up to Rs 832 Crores through the issue of up to 26.49 million shares at Rs 314.11 per share ^[1]. However, the contemporaneous report explicitly states that the filing did not specify how the proceeds would be deployed ^[1]. Accordingly:

• Tier-I allocation: Not quantifiable from the cited filing evidence.
• CAR impact: Cannot be calculated. An eligible Tier-I infusion would increase the capital numerator in the CAR calculation, but the actual uplift depends on the amount classified as regulatory Tier-I capital and the company’s risk-weighted assets.
• Regulatory headroom: Cannot be assessed because the filing evidence does not provide the company’s existing CAR, post-infusion CAR, risk-weighted assets, or the applicable regulatory minimum.

Therefore, any claim that a specific percentage of the issue proceeds was earmarked for Tier-I capital, or that the infusion would raise CAR by a stated number of percentage points above the regulatory requirement, would be unsupported by the cited material.

Verdict: The proposed preferential issue price of Rs 314.11 per share is substantially above the company’s latest full-year book value per share of Rs 81.15—approximately 3.87x book value, or a 287.07% premium. A per-share comparison with the latest equity funding round cannot be established because the reported 2021 transaction was only a proposed fundraise and did not provide a completed issue price or share count.

The FY26 figure is the cleaner annual comparator. The Q1 FY27 book value per share is the latest reported quarterly figure, but it is not an annual audited number.

Funding-round comparison

The only funding-round reference is a November 2021 report that OnEMI was looking to raise USD 50–75 million at a USD 380–420 million valuation; it does not establish that the round closed, nor does it disclose the corresponding number of shares. Therefore, it cannot be converted into a reliable historical per-share valuation or directly compared with Rs 314.11 ^[6].

SEBI ICDR floor-price compliance

Compliance cannot be independently verified from the reported figures. The relevant date cited for the preferential issue was 11 September 2026, and the company subsequently stated that it had applied for in-principle approval under SEBI ICDR and made a valuation report available ^{[3] [7]}. However, the cited exchange material does not provide:

• the prescribed market-price inputs used for the floor-price calculation;
• the resulting SEBI ICDR floor price; or
• an explicit statement that Rs 314.11 was above that computed floor.

Accordingly, the defensible conclusion is “not verifiable from the disclosed calculation,” rather than compliant or non-compliant. The fact that the issue price is well above book value does not itself establish compliance, because the SEBI ICDR floor-price test requires comparison with the applicable regulatory market-price benchmark.